Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 123.75B |
| Revenue (ttm) | 54.48B |
| Net Income (ttm) | 9.18B |
| Shares Out | n/a |
| EPS (ttm) | 1.62 |
| PE Ratio | 13.49 |
| Forward PE | 9.12 |
| Dividend | 1.55 (6.97%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 9,921 |
| Average Volume | 49,246 |
| Open | 21.73 |
| Previous Close | 21.81 |
| Day's Range | 21.73 - 22.20 |
| 52-Week Range | 18.57 - 27.77 |
| Beta | n/a |
| RSI | 61.17 |
| Earnings Date | Aug 5, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Pfizer's yield is high, and so too is its payout ratio.
Pfizer/BioNTech updated COVID vaccine authorized in Canada
Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, Pfizer in focus
Pfizer: This Is What Bulls Waited For
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer Inc . (NYSE: PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle...
Pfizer experimental sickle cell drug fails phase 3 trial
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.
Pfizer experimental sickle cell drug fails phase 3 trial
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.
Pfizer's sickle cell drug fails main goal in late-stage trial
Pfizer said on Friday that its experimental sickle cell disease drug failed to meet the main goal in a late stage trial in patients 16 years of age and older.
Pfizer fails in late-stage trial for sickle cell disease therapy
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
Pfizer beat expectations last quarter and it raised its guidance.
Starboard takes new position in TripAdvisor, adds Salesforce and Pfizer among Q2 moves
How Do Investors Really Feel About Pfizer?
Pfizer's (NYSE: PFE) short percent of float has risen 8.57% since its last report. The company recently reported that it has 107.78 million shares sold short , which is 1.9% of all regular shares tha...
Pfizer shares jump over 5% as Q1 net profit surges 27.2% YoY
Pfizer Ltd’s shares surged 5.4% to ₹5,385 in early trade on Thursday after the pharmaceutical company reported robust first-quarter results for FY26. The company’s net profit grew 27.2% year-on-year (...
FDA considers revoking Pfizer COVID vaccine for children under 5
The Food and Drug Administration is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children under 5 years old, a move that would add another barrier for parents who wa...
July Readers Tagged 9 Ideal Dividend Dogs From 17 "Safer" Of 40 ReFa/Ro Mentions
Prior to July 31, 2025, my REaders mentioned 40 equities in their comments about my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about their ReFa/...
FDA may pull authorization for Pfizer COVID shot for kids under 5
The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children under 5 years old, the company confirmed Wednesday. The move would ad...
FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive.
FDA may pull authorization of Pfizers Covid vaccine for children under 5
The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots against Covid.
4 stocks to watch on Tuesday: ONON, SE, INTC, PFE
Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer
Pfizer's combination therapy improves survival in bladder cancer trial
Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in patients with muscle-invasive bladder cancer when administered before and ...
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from the Phase 3 EV-303 clinical trial (also known a...
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder c...